These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31167847)

  • 21. Seroprevalence of antibodies against varicella zoster virus and rubella virus among newly recruited expatriate healthcare workers: a cross-sectional study.
    Shady I
    BMJ Open; 2018 Mar; 8(3):e019339. PubMed ID: 29567844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Serological diagnostic trial of the causative virus of Bell's palsy by anti-herpes virus antibodies in the paired sera].
    Chida K; Takase S
    Rinsho Shinkeigaku; 2000 Aug; 40(8):791-6. PubMed ID: 11218698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of a commercial Varicella Zoster glycoprotein IgG enzyme immunoassay with a reference time resolved fluorescence immunoassay (VZV TRFIA) for measuring VZV IgG in sera from pregnant women, sera sent for confirmatory testing and pre and post vOka vaccination sera from healthcare workers.
    Maple PA; Breuer J; Quinlivan M; Kafatos G; Brown KE
    J Clin Virol; 2012 Mar; 53(3):201-7. PubMed ID: 22261123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of fifteen commercial assays for detecting Varicella Zoster virus IgG with reference to a time resolved fluorescence immunoassay (TRFIA) and the performance of two commercial assays for screening sera from immunocompromised individuals.
    Chris Maple PA; Gunn A; Sellwood J; Brown DW; Gray JJ
    J Virol Methods; 2009 Feb; 155(2):143-9. PubMed ID: 18996415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in the prevalence of the measles, rubella, varicella-zoster, and mumps virus antibody titers in Japanese pregnant women.
    Hanaoka M; Hisano M; Watanabe N; Sugawara K; Kambe Y; Kanda E; Sago H; Kato T; Yamaguchi K
    Vaccine; 2013 May; 31(19):2343-7. PubMed ID: 23523405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.
    Shinefield H; Black S; Williams WR; Marchant C; Reisinger K; Stewart T; Meissner HC; Guerrero J; Klopfer SO; Xu J; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2005 Aug; 24(8):670-5. PubMed ID: 16094218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neonatal antibody titers against varicella-zoster virus in relation to gestational age, birth weight, and maternal titer.
    van Der Zwet WC; Vandenbroucke-Grauls CM; van Elburg RM; Cranendonk A; Zaaijer HL
    Pediatrics; 2002 Jan; 109(1):79-85. PubMed ID: 11773545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants.
    D'Angio CT; Boohene PA; Mowrer A; Audet S; Menegus MA; Schmid DS; Beeler JA
    Pediatrics; 2007 Mar; 119(3):e574-9. PubMed ID: 17332177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunity of nursing students to measles, mumps, rubella, and varicella in Yozgat, Turkey.
    Kader Ç; Erbay A; Akça NK; Polat MF; Polat S
    Am J Infect Control; 2016 Jan; 44(1):e5-7. PubMed ID: 26442461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.
    Durando P; Esposito S; Bona G; Cuccia M; Desole MG; Ferrera G; Gabutti G; Pellegrino A; Salvini F; Henry O; Povey M; Marchetti F
    Vaccine; 2016 Aug; 34(36):4278-84. PubMed ID: 27423382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between anti-JC-virus and anti-cytomegalovirus, -Epstein-Barr virus and -measles/-rubella/-varicella-zoster-virus antibodies.
    Auer M; Borena W; Holm-von Laer D; Deisenhammer F
    J Med Virol; 2017 Jan; 89(1):3-9. PubMed ID: 27253624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme-linked immunosorbent assay for detection of antibodies to varicella zoster virus.
    Goldberg RD; Sarov I
    Isr J Med Sci; 1980 Feb; 16(2):111-7. PubMed ID: 6245042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The combination measles, mumps, rubella and varicella vaccine in healthy children.
    Arbeter AM; Baker L; Starr SE; Plotkin SA
    Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Habermehl P; Zepp F; Mannhardt W; Kuttnig M; Muttonen P; Prieler A; Maurer H; Bisanz H; Tornieporth N; Descamps D; Willems P
    Pediatr Infect Dis J; 2006 Jan; 25(1):12-8. PubMed ID: 16395096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the performance of the LIAISON VZV-IgG and VIDAS automated enzyme linked fluorescent immunoassays with reference to a VZV-IgG time-resolved fluorescence immunoassay and implications of choice of cut-off for LIAISON assay.
    Maple PA; Rathod P; Smit E; Gray J; Brown D; Boxall EH
    J Clin Virol; 2009 Jan; 44(1):9-14. PubMed ID: 18823815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection.
    Hammond O; Wang Y; Green T; Antonello J; Kuhn R; Motley C; Stump P; Rich B; Chirmule N; Marchese RD
    J Med Virol; 2006 Dec; 78(12):1679-87. PubMed ID: 17063506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility of medical students to vaccine-preventable viral diseases: a serological study.
    Kukino J; Naito T; Mitsuhashi K; Oshima H; Sekiya S; Isonuma H; Watanabe K; Dambara T; Hayashida Y
    J Infect Chemother; 2004 Dec; 10(6):335-7. PubMed ID: 15614457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective Study of Live Attenuated Vaccines for Patients with Nephrotic Syndrome Receiving Immunosuppressive Agents.
    Kamei K; Miyairi I; Ishikura K; Ogura M; Shoji K; Funaki T; Ito R; Arai K; Abe J; Kawai T; Onodera M; Ito S
    J Pediatr; 2018 May; 196():217-222.e1. PubMed ID: 29499990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a multiplex bead immunoassay for determination of immune status to varicella-zoster virus in medical center students and employees.
    Loeffelholz MJ; Prince HE
    Clin Vaccine Immunol; 2015 Mar; 22(3):351-3. PubMed ID: 25589555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.